Braeburn Pharmaceuticals presented data from the Phase 3 study of Probuphine for the long-term maintenance treatment of opioid dependence at the 78th Annual Scientific Meeting of The College on Problems of Drug Dependence (CPDD).
Your search for buprenorphine returned 199 results
Transdermal buprenorphine may be an effective therapy for diabetic peripheral neuropathic pain (DPNP), however it was associated with a high rate of adverse events, mostly nausea and/or vomiting.
Researchers from Baylor College of Medicine and the Veterans Affairs Medical Center in Houston, TX, concluded that the use and expansion of buprenorphine therapy should not be limited or hindered given the strong evidence of efficacy.
At PAINWeek 2012, investigators reported that immediate-release opioids are acceptable for supplemental analgesia when transdermal buprenorphine is being used to manage moderate-to-severe chronic pain.
Among patients experiencing precipitated withdrawal, all were discharged after symptoms resolved, with one self-directed discharge.
Proportion of overdose deaths did not increase in association with actions taken to ease access to buprenorphine
BioDelivery Sciences International, Inc. announced preliminary findings from its Phase 3 study of BioErodible MucoAdhesive (BEMA) buprenorphine for the treatment of moderate to severe chronic pain in a mixed opioid-naive and opioid-experienced population.
Maternal, neonatal outcomes similar to buprenorphine monotherapy
Teva announced the launch of Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets, the generic version of Reckitt Benckiser’s Suboxone.
The FDA has identified 305 cases of dental problems with buprenorphine-containing medicines dissolved in the mouth.